BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» Proclara lands $47M series E, focuses on Alzheimer's end 'GAIM'
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Proclara lands $47M series E, focuses on Alzheimer's end 'GAIM'
Sep. 8, 2016
By
Marie Powers
No Comments
Neurophage Pharmaceuticals Inc. re-branded itself as Proclara Biosciences as it hauled in a $47 million series E and moved lead candidate, NPT088, into a phase Ib trial in Alzheimer's disease (AD).
BioWorld